Celldex (CLDX) shares fell over 14% after hours as it ended development of barzolvolimab for eosinophilic esophagitis. The Phase 2 trial met its goal of mast cell reduction but failed to show clinical benefit. Celldex will refocus on barzolvolimab's late-stage programs in chronic spontaneous urticaria, atopic dermatitis, and other conditions, which investors see as bigger opportunities.